MRC Council member
Professor Simon Hollingsworth is a member of the Medical Research Council (MRC) Council.
Professor Hollingsworth is Vice President and Global Franchise Head for IO Bispecifics at AstraZeneca. In his current role, he leads the late-stage development, global registration and commercialisation of AstraZeneca’s portfolio of novel immune oncology bispecific agents.
Previously, he was Vice President and Global Medicine Leader for Lynparza at AstraZeneca where he led life cycle development of Lynparza to becoming a multi blockbuster medicine approved globally for the treatment of ovarian, breast, pancreatic and prostate cancers.
Professor Hollingsworth is a visiting professor in the Division of Cancer Studies at King’s College London, a Fellow of the Royal College Pathologists, Fellow of the British Pharmacological Society, Fellow of the Academy of Medical Sciences and serves on multiple national and international science funding and review panels and advisory boards.
He brings over 25 years of experience in drug and therapeutics development across industry and academic careers centred on clinical drug development and precision medicine in oncology.
Last updated: 1 September 2023